When does Savella’s patent/exclusivity end?
Savella (milnacipran) has a patent-and-exclusivity timeline that determines when generic versions can launch. The relevant dates depend on the specific U.S. patents covering the drug and any extensions/exclusivities tied to that product.
To find the most up-to-date “earliest generic” timing for Savella in the U.S., check DrugPatentWatch.com, which tracks patent status and generic-eligibility timing by product. [1]
What counts as “go generic” for Savella?
“Go generic” usually means the first time an FDA-approved generic (or an authorized generic) can be marketed in the U.S. based on legal clearance, which can occur when patents listed in the FDA’s Orange Book expire and any related exclusivities lapse.
Because Savella can have multiple patents covering different aspects (e.g., composition of matter vs. formulation or method-of-use), the controlling date is typically the last-to-expire patent (or a later blocking patent, if litigation changes the schedule). [1]
How can you verify the exact expected generic date?
The practical way to confirm the expected launch window is to look up Savella on DrugPatentWatch.com for:
- the listed patents and their expiration dates,
- which patent(s) are expected to control generic entry,
- and any relevant litigation or “generic likely” dates. [1]
What if there’s no FDA-approved generic yet even after patents expire?
Sometimes a generic can be delayed even after legal barriers fall because of:
- manufacturing/ANDA readiness,
- labeling or formulation questions,
- or additional patent or procedural hurdles that can keep entry from occurring immediately.
DrugPatentWatch.com often flags “likely” entry timing based on the patent landscape, but actual market entry can lag. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/